A 13% decline in the past year continues downward. Some of the decline might be explained by pandemic-related drop in healthcare utilization.
The opioid epidemic is hardly over, but Prime Therapeutics, the PBM for 23 Blues plans, is seeing notable declines in a number of measures of opioid prescribing among its claims.
In a review of it claims data from 16 million commercial members over the past year, Prime found a 13% decline in the number of members with an opioid claim and a similar reduction (12%) in members with a prescription for a high dose of opioids (90 morphine milligram equivalents or above).
“Obviously it is a good thing, we think, if there are fewer people getting opioids prescribed to them, because there are just a few instances when you actually need an opioid for pain control,” Cathy Starner, Pharm.D., health outcomes consultant senior principal, said in a recent interview with MHE.
Starner said the decline in opioid prescriptions be partly because of the pandemic-related decline in healthcare utilization, which was particularly steep during April and May of last year. But she also noted that the decline in opioid prescriptions among Prime’s claim goes back several years, so the recent decline is part of longer-term trend.
Prime has also seen a decline in its claims in the average days’ supply of opioids, from 16 to 15 days.
“Instead of you getting the seven-day supply day, when you are getting 50 tablets or whatever might be, you are getting 20 tablets for a three-day supply,” said Starner.
Prime, which is headquartered in Eagan, Minnesota, a Twin Cities suburb, has several programs designed to curb excessive and potentially harmful opioid prescribing, including utilization management at the point of sale. “If you are getting aprescription for the first tine and you don’t have any claims in your history, you probably don’t need a high dose or a large supply of an opioid,” Starner said.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More